Business Description
Mereo BioPharma Group PLC
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 14.19 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.31 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 15.52 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 60.4 | |||||
3-Year EPS without NRI Growth Rate | 39.9 | |||||
3-Year FCF Growth Rate | 34.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 48.09 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 94.83 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28.09 | |||||
9-Day RSI | 36.26 | |||||
14-Day RSI | 42.65 | |||||
6-1 Month Momentum % | 62.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.07 | |||||
Quick Ratio | 6.07 | |||||
Cash Ratio | 5.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.5 | |||||
Shareholder Yield % | 1.19 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -167.26 | |||||
ROE % | -34.64 | |||||
ROA % | -26.48 | |||||
ROIC % | -124.28 | |||||
3-Year ROIIC % | -57.8 | |||||
ROC (Joel Greenblatt) % | -1282.31 | |||||
ROCE % | -31.36 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 53.88 | |||||
PB Ratio | 8.01 | |||||
Price-to-Tangible-Book | 7.96 | |||||
EV-to-EBIT | -26.65 | |||||
EV-to-EBITDA | -27.35 | |||||
EV-to-Revenue | 54.8 | |||||
EV-to-FCF | -33.02 | |||||
Price-to-Net-Current-Asset-Value | 8.13 | |||||
Price-to-Net-Cash | 9.15 | |||||
Earnings Yield (Greenblatt) % | -3.75 | |||||
FCF Yield % | -2.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Mereo BioPharma Group PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 9.17 | ||
EPS (TTM) (€) | -0.139 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 42.65 | ||
14-Day ATR (€) | 0.157066 | ||
20-Day SMA (€) | 3.9985 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 2.36 - 4.45 | ||
Shares Outstanding (Mil) | 153.85 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mereo BioPharma Group PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mereo BioPharma Group PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Mereo BioPharma Group PLC Frequently Asked Questions
What is Mereo BioPharma Group PLC(HAM:MAH0)'s stock price today?
When is next earnings date of Mereo BioPharma Group PLC(HAM:MAH0)?
Does Mereo BioPharma Group PLC(HAM:MAH0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |